However, Omacetaxine mepesuccinate (SynriboTM), a plant alkaloid approved for chronic myeloid leukemia [41] and effective in triple-negative breast cancer [42], has recently been reported to act as a chemical inhibitor of NRF2 [43]. Here, NFE2L2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.